Check out these newsworthy studies from the Dec. 7, 2016, issue of JNeurosci. Media interested in obtaining the full text of the studies should contact email@example.com.
A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world's first treatment to impede the progression of Parkinson's disease following publication of research findings today in the journal Science Translational Medicine.
People with Parkinson's disease and cognitive impairment have disruptions in their brain networks that can be seen on a type of MRI, according to a new study.
Misfolded proteins associated with Parkinson's disease were detected in cerebrospinal fluid by scientists at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), paving the way to development of a biochemical test to diagnosis the disease.
An interdisciplinary team of researchers from the Vanderbilt Institute for Integrative Biosystems Research and Education (VIIBRE) has developed a microfluidic device containing human cells which faithfully mimics the behavior of the blood-brain barrier and used it to gain new insights into brain inflammation, which can be caused by injury or infections such as meningitis and encephalitis.
A team of researchers led by a biomedical scientist at the University of California, Riverside has found that two sibling RNA-binding proteins (PTBP1 and PTBP2) serve both redundant and unique functions in the developing brain when neural stem cells are changed into neurons, providing insight into how neurons are formed.
In Neuron, a team at Cold Spring Harbor Laboratory (CSHL) reveals for the first time the structure of a portion of an important brain cell receptor, called the NMDA (N-methyl D-aspartate) receptor. The newly mapped portion of NMDA receptor is responsible for recognizing zinc, an element common throughout the brain that can inhibit a class of NMDA receptors.
Axial Biotherapeutics announced that researchers from Caltech led by Dr. Sarkis Mazmanian, the company's scientific founder, have discovered a novel biological link between the gut microbiome and Parkinson's disease (PD). In a validated PD mouse model, gut bacteria were shown to promote hallmark disease processes including inflammation of the nervous system and motor dysfunction. The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson's disease.
Caltech researchers have discovered that gut bacteria play a major role in the symptoms of Parkinson's disease.
Gut microbes may play a critical role in the development of Parkinson's-like movement disorders in genetically predisposed mice, researchers report Dec. 1 in Cell. Antibiotic treatment reduced motor deficits and molecular hallmarks of Parkinson's disease in a mouse model, whereas transplantation of gut microbes from patients with Parkinson's disease exacerbated symptoms in these mice. The findings could lead to new treatment strategies for the second most common neurodegenerative disease in the United States.